{"id":408304,"date":"2021-01-05T07:33:26","date_gmt":"2021-01-05T12:33:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408304"},"modified":"2021-01-05T07:33:26","modified_gmt":"2021-01-05T12:33:26","slug":"dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zo5KTdpe5l01-eoLe1fx1xi0oqS4xHeUGXr63rhZWdA5pOK9M3tDY4tm8RKZG8DPBKk77SZ_hdklzhkLWPuoYSkOrnGd8AdBK6Lywxesj-4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dyne Therapeutics, Inc<\/a>. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.<\/p>\n<p>A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nf9OqLTwf5AO4hbgQ6Mhz6jYjPESn6DYZxj8OCkDtJc9tWtBpF85XemDYI7aLtbHLjEy29AwqMjASiesxZBR1-VxXLT4f4ov_uyLuP_DMeE57Irn5NHq7wUix27Nv3hWe4Hq0nIQt7X3lxZU_XiIANWXO9Vgujj3U_c846rwr7w=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/investors.dyne-tx.com\/investors-and-media<\/a> and a replay will be accessible for 90 days following the presentation.<\/p>\n<p>\n        <strong>About Dyne Therapeutics<\/strong>\n      <\/p>\n<p>Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE\u2122 platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I5cPAogtAEgLN3AeZ3JoVSht1ERxYzhuYJOQUgyTPUaD7fKW24sN7JkthrdQvKSqnvAgjbJ4OQcybJLLFM3M9g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.dyne-tx.com<\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b0GZ-4zSnPHrBjAhgKkVxDGJZbGGs8Y6vbyatq9yuR877qY5yBjudfFY_1GT5Hb0c5Skb6mH8CpoS7VeAvt1Eg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5LEGYIreCEQKbSKSk-ZT69FEujECXiK12tEhDwTcBDi8RH5Y-iyC8-Xj8Ai16YYbqBSrGoMQ6AgLEPE_NPHUgXKwrplR3Z3rvfLFDWd6KqM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KIz11rxBpGetDuHNqRmhZo4o4lPVynFwkZB1BWvoaDymryt-jMGKYBB-8dNv3_DVp0y9-F05_YaMJv_ZZrijVSa6RCnz-2z6wgsA1uVjLL8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Dyne Therapeutics<br \/>Amy Reilly<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EaHvdpw1Zs-b8Bm9ScHYUJzTUja8HUUByHNpHcLSNeIgau9-2xhlWy35J24crJZmdbCeHnHs5TPj7BnftZj4bs-u0hSRfHQhKhTSDrmi36w=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">areilly@dyne-tx.com<\/a><br \/>857-341-1203 <\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/80905634-c682-4c65-83d3-c9d18a8cfb0a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/investors-and-media and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408304","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/investors-and-media and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with &hellip; Continue reading &quot;Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T12:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-05T12:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\",\"datePublished\":\"2021-01-05T12:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at https:\/\/investors.dyne-tx.com\/investors-and-media and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with &hellip; Continue reading \"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T12:33:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-05T12:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/","name":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=","datePublished":"2021-01-05T12:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDczMiMzOTAzOTc3IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408304","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408304"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408304\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}